NYSE:OGNPharmaceuticals
Organon (OGN) Stock Valuation After FDA Expands TOFIDENCE Approval In US Biosimilars Market
Organon (OGN) is back in focus after the US Food and Drug Administration approved an expanded label for its tocilizumab biosimilar, TOFIDENCE, adding indications for severe cytokine release syndrome and certain hospitalized COVID-19 patients.
See our latest analysis for Organon.
At a latest share price of US$13.44, Organon’s 90 day share price return of 111.65% and year to date share price return of 85.64% contrast with a 3 year total shareholder return that declined 27.03%. This suggests...